Stock Analiz

Pliant Therapeutics, Inc. PLRX

Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026

$0.70Market cap $43M
Open the interactive analysis →

Pliant Therapeutics, Inc. (PLRX) is a healthcare company listed in the US with a market value of about $43M.

Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -41%.

About Pliant Therapeutics

Pliant Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2020. Revenue went from $57M in 2019 to $2M in 2023, a decline of about 59.2% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 46% over three years (dilution for shareholders).

Score: 0.4 / 5

Value0/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-154.6%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-4256.3%
ROIC (5-yr avg.)-41.2%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 7 years

Fiscal year2025202420232022202120202019
Revenue$0$0$2M$10M$8M$42M$57M
Net income-$149M-$210M-$161M-$123M-$97M-$42M-$631000
Free cash flow-$129M-$159M-$117M-$96M-$77M-$39M-$4M
EPS (diluted)$-2.43$-3.47$-2.75$-2.94$-2.71$-1.95$-4.22
Net margin——-10211.1%-1273.3%-1284.5%-99.3%-1.1%
ROIC-58.7%-49.5%-30.0%-30.5%-37.4%-11.6%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 1 analysts is $2.00, 187% above the current price; targets range from $2.00 to $2.00; the consensus rating is “Hold”; expected EPS is $-1.44 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Pliant Therapeutics pay a dividend?

Not currently.

Is Pliant Therapeutics a good stock to buy?

We do not give buy or sell advice. Pliant Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.